2012 - Fellow of the American Association for the Advancement of Science (AAAS)
His scientific interests lie mostly in Internal medicine, Oncology, Cancer, Breast cancer and Gynecology. Internal medicine and Germline mutation are frequently intertwined in his study. He has researched Oncology in several fields, including Cohort, Carcinoma, Prostate cancer, Family history and Risk assessment.
His Cancer research includes themes of Mutation, Immunology, Pathology, Genetic counseling and Genetic testing. His Breast cancer research is multidisciplinary, incorporating perspectives in Ovarian cancer and Genotype. His Gynecology research integrates issues from Proportional hazards model and Risk factor.
Mark E. Robson spends much of his time researching Internal medicine, Oncology, Breast cancer, Cancer and Germline. His Internal medicine study often links to related topics such as Germline mutation. As part of one scientific family, Mark E. Robson deals mainly with the area of Oncology, narrowing it down to issues related to the Metastatic breast cancer, and often PARP inhibitor.
He usually deals with Breast cancer and limits it to topics linked to Gynecology and Risk factor. His research investigates the link between Cancer and topics such as Genetic testing that cross with problems in Genetic counseling and Family medicine. The Germline study which covers Cancer research that intersects with Gene and Cancer predisposition.
His primary areas of study are Internal medicine, Oncology, Breast cancer, Cancer and Germline. His study in the fields of BRCA mutation, Metastatic breast cancer, Cohort and Stage under the domain of Internal medicine overlaps with other disciplines such as In patient. His Oncology research incorporates themes from Pembrolizumab, Olaparib, Chemotherapy, CHEK2 and Triple-negative breast cancer.
His Breast cancer study incorporates themes from Odds ratio, Sequencing data, Mutation, Hazard ratio and Single-nucleotide polymorphism. His study in Cancer is interdisciplinary in nature, drawing from both Exact test and Genetic testing. His studies deal with areas such as Cancer research, Germline mutation, PALB2, Cancer predisposition and Renal cell carcinoma as well as Germline.
Mark E. Robson mainly investigates Internal medicine, Oncology, Cancer, Germline and Gene. His Internal medicine research includes elements of CHEK2 and Guideline. Mark E. Robson combines subjects such as Fertility preservation, BRCA mutation and Cyclophosphamide, Chemotherapy with his study of Oncology.
His Cancer study combines topics from a wide range of disciplines, such as First-degree relatives, Complex segregation analysis and Genetic testing. Mark E. Robson has included themes like Germline mutation, PALB2 and Lung cancer in his Germline study. His studies in Gene integrate themes in fields like Odds ratio, Family Cancer History and Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir;Ryma Benayed;Ronak H Shah;Aijazuddin Syed.
Nature Medicine (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson;Seock Ah Im;Elżbieta Senkus;Binghe Xu.
The New England Journal of Medicine (2017)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Andrew Tutt;Mark Robson;Judy E Garber;Susan M Domchek.
The Lancet (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer
A Tutt;M Robson;J E Garber;S M Domchek.
The Lancet (2010)
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Noah D. Kauff;Jaya M. Satagopan;Mark E. Robson;Lauren Scheuer.
The New England Journal of Medicine (2002)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Colin C. Pritchard;Joaquin Mateo;Michael F. Walsh;Navonil De Sarkar.
The New England Journal of Medicine (2016)
Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk
Douglas Frederick Easton;Paul David Pharoah;Antonis C. Antoniou;Marc Derek Tischkowitz.
The New England Journal of Medicine (2015)
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility
Mark E. Robson;Mark E. Robson;Angela R. Bradbury;Banu K Arun;Susan M. Domchek.
Journal of Clinical Oncology (2010)
A note on competing risks in survival data analysis
J M Satagopan;L Ben-Porat;M Berwick;M Robson.
British Journal of Cancer (2004)
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
Steven A. Narod;Jean Sébastien Brunet;Parviz Ghadirian;Mark Robson.
The Lancet (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: